Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th ...
– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD – – Additional analyses will assess glucocorticoid-associated toxicity and vaccine responses – WALTHAM, Mass., …